First-line Helicobacter pylori Eradication with Standard Triple Therapy and Concomitant Therapy: A Retrospective Study

Abstract

Background/Aims: The eradication rate of Helicobacter pylori with standard triple therapy as a first-line treatment has decreased to 70∼85%. Recently, concomitant therapy has been reported to overcome this decrease in eradication rate to some degree. The aim of this retrospective study was to compare the efficacy of 7-day concomitant therapy with that of 7-day standard triple therapy as a first-line treatment. Materials and Methods: Between March 2013 and February 2017, the medical records of 261 patients who received 7-day standard triple therapy or 7-day concomitant therapy as a first-line H. pylori eradication therapy were retrospectively evaluated. Successful eradication was confirmed using the ¹³C-urea breath test 6 to 8 weeks after the end of the eradication therapy. Results: This study included 261 patients, 140 patients in the standard triple therapy group and 121 in the concomitant therapy group. The H. pylori eradication rate by intention-to-treat analysis was 60.0% in the standard triple therapy group and 81.0% in the concomitant therapy group (P＜0.001). In the per-protocol analysis, the H. pylori eradication rates in the standard triple therapy and concomitant therapy groups were 69.4% and 88.3%, respectively (P＜0.001). Conclusions: Concomitant therapy was more effective as a first-line H. pylori eradication therapy than the standard triple therapy.

Keywords

• Concomitant therapy
• Disease eradication
• Helicobacter pylori
• Standard therapy